(HealthDay News) — For men aged 50 years or older with symptomatic benign prostatic hyperplasia (BPH) and a prostate size between 20 and 80 g, minimally invasive surgery with the Optilume BPH Catheter System provides sustained improvements in obstructive symptoms and flow rate, according to a study published in the September issue of The Journal of Urology.

Steven A. Kaplan, MD, from the Icahn School of Medicine at Mount Sinai in New York City, and colleagues randomly assigned men aged 50 years or older with symptomatic BPH and a prostate size between 20 and 80 g to receive treatment with Optilume BPH or a sham surgical procedure (100 active, 48 sham) at 18 centers in the United States and Canada.

The researchers found that at 1 year after treatment, participants randomly assigned to Optilume BPH had a reduction in the International Prostate Symptom Score of 11.5 ± 7.8 points compared with a reduction of 8.0 ± 8.3 points in the sham arm at 3 months. Treatment with Optilume BPH improved the flow rate, with improvement of +10.3 mL/s from baseline to 1 year.

Continue Reading

“This minimally invasive treatment represents an attractive option to patients looking to maintain sexual function while achieving durable symptom relief and improved flow,” the authors write.

The study was funded by Urotronic, which manufactures the Optilume BPH Catheter System.

Abstract/Full Text